Update on pharmacotherapy of myoclonic seizures.

Abstract

INTRODUCTION:

Myoclonic seizures are brief, involuntary muscular jerks arising from the central nervous system that can occur in different epilepsy syndromes, including idiopathic generalized epilepsies or the most severe group of epileptic encephalopathies. Valproate is commonly the first choice alone or in combination with some benzodiazepines or levetiracetam. However, more treatment options exist today as there is emerging evidence to support the efficacy of some newer antiepileptic drugs. In addition, of major importance remains avoidance of medications (e.g., carbamazepine, phenytoin) that may aggravate myoclonic seizures. This is an updated review on the available therapeutic options for treatment of myoclonic seizures. Areas covered: Key efficacy, tolerability and efficacy data are showed for different antiepileptic drugs with antimyoclonic effect, alone and/or in combination. Expert opinion: Pharmacological treatment of myoclonic seizures is based on clinical experience with little evidence from randomized clinical trials. Valproate, levetiracetam, and some benzodiazepines, are widely used. There is still insufficient evidence for the use of other antiseizure drugs, such as topiramate or zonisamide as monotherapy. Better understanding of pathophysiologic mechanisms of myoclonic epilepsies could yield great improvement in the treatment and quality of life of patients.

• Authors: Pasquale Striano, Vincenzo Belcastro
• Journal: Expert opinion on pharmacotherapy (Expert Opin Pharmacother) Vol. 18 Issue 2 Pg. 187-193 (Feb 2017) ISSN: 1744-7666 [Electronic] England
• PMID: 28067060 (Publication Type: Journal Article, Review)

Chemical References

• Anticonvulsants

Topics

• Anticonvulsants (therapeutic use)
• Epilepsies, Myoclonic (drug therapy)
• Epilepsy, Generalized (drug therapy)
• Humans
• Quality of Life
• Randomized Controlled Trials as Topic